Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer

Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer is a phase 2 interventional study registered as NCT07039526 by John Waters, with 50 participants planned, started 2025-08-19 and due to reach its primary completion in 2027-12. Interventions recorded: CYTALUX™ (pafolacianine) injection preoperatively. Conditions recorded: Esophageal Cancer, Gastrointestinal Cancers, Gynecologic Cancers.

Linked to the drug Pafolacianine because the registry names it among its interventions and Oesophageal cancer among its conditions. Registry record only: no result has been read by an editor.